A research team led by Prof. Wan Yinhua from the Institute of Process Engineering of the Chinese Academy of Sciences has ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH) therapy, but new data has dented optimism about ...